Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...
Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...
A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...
The initial rollout of Eli Lilly's weight loss drug Zepbound in the UK will first go to those with the great clinical need ...
Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of ...
Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable ...
Eli Lilly ( NYSE:LLY) has been making headlines recently with its weight-loss drug Zepbound (tirzepatide). Eli Lilly's weight ...